What we do—

Changing the world

UCLB is the commercialisation company of UCL and its partner NHS Trusts. We bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives.

Read More
Latest news—

UCLB launches applications for social challenge with London Borough of Camden

Are you developing an innovative piece of technology or research idea, at UCL, that has the potential to benefit society? Perhaps your project could be the key to solving a challenge in your local community.

UCLB, part of UCL Innovation & Enterprise, is working with Camden Council to match a pioneering UCL project to help solve a key challenge in the borough – Transitioning to a zero-carbon economy.

Read More
Featured Technology—

Quadruplex-binding compounds – a novel anticancer strategy

We have a first-in-class optimized small-molecule drug candidate ready for IND enabling studies with superior efficacy and activity against pancreatic cancer compared to existing agents, together with a distinct mechanism of action.

Read more
Spotlight—

How does Portico Ventures support non-patentable and fast-to-deploy technologies?

The following interview took place in April 2019 towards the end of the one-year pilot phase of Portico Ventures. Following positive feedback from the Department of Computer Science where the pilot ran, Portico Ventures is now rolling out more widely across the university. Visit our newsroom to find out more.

Read More
Featured Technology—

SnakeGrid

SnakeGrid is a way of developing low-distortion coordinate systems for large engineering projects.

Read more

Latest news and highlights

Read More News

UCLB launches applications for social challenge with London Borough of Camden

/ UCLB News
Are you developing an innovative piece of technology or research idea, at UCL, that has the potential to benefit society? ...

DiNAQOR AG Announces Research Collaboration and License Agreement with UCL to Investigate Gene Therapies for Heart Failure

/ UCLB News
DiNAQOR AG, a global gene therapy platform company, today announced a research collaboration and exclusive license agreement with UCL to ...

UCL developed FVIII gene therapy treatment shows excellent results

/ UCLB News
A FVIII gene therapy treatment, developed by world leading gene therapy expert, Professor Amit Nathwani at UCL has shown positive ...

Syncona makes a further $80 million commitment to Freeline

/ Spinout News
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, has announced Syncona Ltd (Syncona) has ...

FIND THE RIGHT MATCH

Whether you’re an academic or looking for technologies, find your UCLB contact here.

 

Commercialising technology since 1993

0
Active spinouts
0
Active licences in 2018
0
Drug discoveries
0
New patent applications